Search Results

Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored. Read full article

autophagy deficiency in myeloid cells "Background Eosinophilic inflammation is a hallmark of refractory chronic

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome

Yamina Berchiche discuss how a passion for translational science led him to investigate chronic pain The conversation touches on mentorship, imposter syndrome, and the critical importance of creating space pharmacologist who uses in vitro and in vivo models to discover and characterize novel treatments for chronic sites and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic

Initially set on a finance track, it was a chronic pain condition and the limitations of opioid-based pushing him to explore more effective, long-lasting therapeutic strategies — particularly in the realm of chronic Venetia Zachariou's lab to study the effects of chronic pain and addiction/withdrawal on the mesocorticolimbic physician-scientist, with a focus on translational in vitro and in vivo model development for studying chronic

Join me and learn more about how Kari studies GPCRs in basal ganglia circuits following chronic alcohol